CFD RESEARCH CORPORATION — Department of Defense SBIR Phase II: CBD212-006
CFD RESEARCH CORPORATION — SBIR Phase II award from Department of Defense.
- Amount
- $548,493
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase II
- Topic
- CBD212-006
- Solicitation
- 21.2
- NAICS
- —
- Place of performance
- AL
- Period
- 2023-05-15 → 2025-05-18
Description
This project seeks to develop a new broad-spectrum antiviral drug against viruses from the Bunyavirales family. These viruses have been designated as being among the highest potential to cause the next pandemic. CFD Research is advancing a natural product-derived antiviral chemistry that has demonstrated strong in vitro potency against Bunyaviruses with low cytotoxicity. We seek to produce an optimized lead candidate from this project.